Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
03 nov. 2023 12h00 HE
|
Allogene Therapeutics, Inc.
Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic Cancers...
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
02 nov. 2023 16h02 HE
|
Allogene Therapeutics, Inc.
Preclinical Posters to Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on the Next Generation AlloCAR T™ Platform Cloak ™ and Dagger™ Technologies Highlighted Potential...
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
02 nov. 2023 09h00 HE
|
Allogene Therapeutics, Inc.
Comprehensive Review of Overall Treatment Safety Profile of our ALLO-501/501A Candidate Used in Conjunction with Propriety Lymphodepletion with Investigational ALLO-647 from the Phase 1 ALPHA/ALPHA2...
Allogene Therapeutics Announces Participation in November Investor Conferences
30 oct. 2023 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
26 oct. 2023 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
16 oct. 2023 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
27 sept. 2023 09h09 HE
|
Allogene Therapeutics, Inc.
Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate...
Allogene Therapeutics Announces Participation in September Investor Conference
05 sept. 2023 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Appoints Earl Douglas as General Counsel
14 août 2023 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
02 août 2023 16h02 HE
|
Allogene Therapeutics, Inc.
Presented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed/Refractory Large B Cell Lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting and...